Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR Authors: Jonas Gmeiner, Lukas Stolz, Karl-Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Christoph Pauschinger, Wolfgang Rottbauer, Mohammad Kassar, Bjoern Goebel, Paolo Denti, Paul Achouh, Tienush Rassaf, Manuel Barreiro-Perez, Peter Boekstegers, Andreas Rück, Monika Zdanyte, Marianna Adamo, Flavien Vincent, Philipp Schlegel, Sebastian Rosch, Mirjam G Wild, Christian Besler, Stefan Toggweiler, Stephanie Brunner, Julia Grapsa, Tiffany Patterson, Holger Thiele, Tobias Kister, Giuseppe Tarantini, Giulia Masiero, Marco De Carlo, Alessandro Sticchi, Fabian Voss, Amin Polzin, Antonio Popolo Rubbio, Francesco Bedogni, Thorald Stolte, Thomas Nestelberger, Thomas Benito-Gonzales, Enrique Sánchez-Muñóz Published: 2026 ABSTRACT AbstractIntroductionThe impact of coexisting left-sided valvular heart disease (VHD) on clinical outcomes following tricuspid valve edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR) remains unclear, particularly under real-world conditions. To evaluate the prevalence and prognostic impact of concomitant left-sided VHD in patients undergoing T-TEER.MethodsThis study included all patients undergoing T-TEER from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR; NCT06307262) with complete echocardiographic data on left-sided valve disease. Study endpoints included survival and heart failure hospitalizations (HFH) at 2 years, NYHA functional class, and TR reduction.ResultsAmong a total of 1647 eligible patients, 95.8%, 35.6%, and 3.8% had ≥mild, moderate, and severe concomitant VHD, respectively. Moderate or higher VHD was associated with a significantly reduced 2-year survival (P < .001) and reduced 2-year HFH-free survival (P = .005). Multivariate regression analysis confirmed ≥ moderate VHD to be an independent predictor of mortality (hazard ratio 1.54, 95% CI 1.21–1.96, P < .001). Despite worse TR and NYHA functional class at baseline in patients with ≥moderate VHD, T-TEER was associated with a significant TR reduction (P < .001) and symptomatic improvement (P < .001).ConclusionConcomitant left-sided VHD is common among patients undergoing T-TEER and is independently associated with worse survival and higher rates of HFH. Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.Keywords: Multivalvular disease, Aortic regurgitation, Aortic stenosis, Mitral regurgitation, Mitral stenosis, Tricuspid regurgitation Introduction Tricuspid regurgitation (TR) is associated with considerable morbidity and mortality, as well as a marked impairment in quality of life.1 Historically, the limited availability of low-risk treatment options contributed to the underappreciation of TR in clinical practice. In recent years, tricuspid valve transcatheter edge-to-edge repair (T-TEER) has gained recognition as a safe, less-invasive, and efficacious therapeutic option for patients with clinically relevant TR.2,3 In the randomized controlled TRILUMINATE and Tri.FR trials, T-TEER led to a significant improvement in quality of life compared to optimal medical therapy alone.4,5 Beyond that, recently published 2-year follow-up data reported a reduction in the cumulative incidence of heart failure hospitalization (HFH) for patients undergoing T-TEER.6 However, the TRILUMINATE and Tri.Fr trials imposed strict inclusion criteria, among other comorbidities, leading to the exclusion of patients with relevant concomitant left-sided valve disease.7 Under real-world conditions, many patients present with concomitant disease of the mitral or aortic valve, but data on the prognostic impact of multivalvular heart disease in the setting of T-TEER are scarce and mainly limited to patients with severe mitral regurgitation or aortic stenosis presenting with concomitant TR.8,9 To our knowledge, no large multicentre registry has comprehensively assessed the independent prognostic impact of thoroughly graded left-sided valvular disease across the full severity spectrum in T-TEER patients. Therefore, this study aimed at assessing the prevalence as well as the clinical impact of coexisting left-sided valve disorders in patients undergoing T-TEER, utilizing data from the large international European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR). Methods Study cohort and procedural technique The ongoing EuroTR comprises patients who underwent T-TEER for symptomatic TR between 2016 and 2024. Details regarding the registry have previously been published.10–12 For the current analysis, individuals were excluded if they had undergone concomitant mitral TEER (M-TEER) or if echocardiographic data on concomitant left-sided valve disease severity were missing (Supplementary Table S1). At the time of evaluation, all patients continued to experience symptoms despite receiving the maximally tolerated doses of diuretic therapy. Treatment decisions were made following assessment by a multidisciplinary heart team, typically composed of specialists in heart failure, cardiac surgery, and interventional cardiology. T-TEER procedures were performed using either the PASCAL system (Edwards Lifesciences, Irvine, CA, USA) or the MitraClip/TriClip system (Abbott, Santa Clara, CA, USA). The study was conducted in compliance with the Declaration of Helsinki and received appropriate ethical approval (NCT06307262). Study variables and endpoints Baseline clinical variables encompassed demographic data (age and sex), prevalent comorbidities such as systemic arterial hypertension, prior myocardial infarction, coronary artery disease, history of stroke, and diabetes mellitus. Symptoms related to heart failure were systematically recorded, including dyspnoea as classified by the New York Heart Association (NYHA) functional scale, peripheral oedema, ascites, jugular venous distension, and the presence of pleural effusion. Echocardiographic assessments were conducted in accordance with established guideline recommendations using the effective regurgitation orifice area, and biplane vena contracta measurement was used whenever possible.13,14 TR severity was assessed using a five-grade scale15: mild (1+), moderate (2+), severe (3+), massive (4+), and torrential (5+). Mitral valve regurgitation was assessed using a four-grade scale, while all other valve disease was assessed using a three-grade scale. The cohort was divided into patients with or without concomitant ≥ moderate valvular heart disease. The primary endpoint of the study was all-cause mortality at 2 years. Secondary endpoints included survival free from heart failure-related hospitalizations and changes in NYHA functional class at the most recent clinical follow-up. Subgroup analysis assessed patients with concomitant VHD of mild, moderate, and severe degrees, as well as individual left-sided valve disease. Systematic echocardiographic follow-up of left-sided valve lesions (MR, AS, AR, and MS) was not available across the registry and could therefore not be incorporated into the present analysis. Statistical analysis Statistical analysis was performed using IBM SPSS (version 28.0.0.0). Normally distributed continuous variables were reported as mean ± standard deviation, non-normally distributed continuous variables as median with interquartile ranges, and categorical variables were reported as percentages. Students' t-test, Mann-Whitney U test, and Wilcoxon test were used to compare groups as appropriate. All tests were two-tailed, and P-values <.05 were considered significant. Mortality rates were calculated using the Kaplan–Meier method, comparisons were made by log-rank tests, and Kaplan–Meier curves were plotted using GraphPad Prism version 8. Results Baseline characteristics and overall outcomes Among a total of 3048 patients in the EuroTR, 1647 patients did not undergo concomitant M-TEER and had complete echocardiographic data on concomitant left-sided valve disease and were therefore included in the present analysis (Figure 1). Baseline characteristics of the study cohort are presented in Table 1. Patients exhibited advanced surgical risk as indicated by the EuroScore II (6.5 ± 7.2%) and TRI-Score (5.7 ± 2.0) and were predominantly female (54.1%), with a preserved left ventricular ejection fraction (53.0 ± 10.9%). TR was successfully reduced to ≤ moderate and ≤mild in 74.8% and 31.9% of patients, respectively. At the 2-year follow-up, all-cause survival and survival free from HFH were 70.4% and 58.7% (Figure 2). T-TEER was associated with a significant improvement in the NYHA functional class and durable reduction of TR at the latest available follow-up (Supplementary Figure S1). Left ventricular stroke volume increased significantly between baseline and the latest available follow-up (47.5 (37.0–58.1) ml vs. 49.0 (38.0–60.7) ml, P = .006). Study flowchart. The figure shows the study flowchart. Patients undergoing M-TEER and patients with incomplete echocardiographic data were excluded from this analysis. M-TEER = mitral transcatheter-edge-to-edge-repair Table 1Baseline characteristics of patients with and without concomitant ≥ moderate VHDTotal cohortN = 1647Without concomitant ≥ moderate VHDn = 1061With concomitant ≥ moderate VHDn = 586 P-value*Age (years)78.8 ± 7.878.6 ± 8.379.4 ± 6.8 .026 BMI (kg/m2)25.0 (22.4–28.3)25.2 (22.7–28.5)24.6 (22.0–27.7) <.001EuroScore II6.5 ± 7.26.4 ± 7.06.7 ± 7.4.408TRI-Score5.7 ± 2.05.5 ± 2.05.9 ± 1.9.006Male sex756 (45.9)506 (47.4)250 (42.7).056H/o myocardial infarction141 (10.1)96 (10.5)45 (9.4).487COPD236 (15.2)151 (15.0)85 (15.7).692PAD180 (13.0)120 (13.2)60 (12.5).727Diabetes mellitus179 (21.7)228 (21.8)122 (21.6).903H/o stroke179 (12.7)115 (12.5)64 (13.1).759H/o cardiac surgery395 (25.4)252 (24.9)143 (26.4).529H/o tricuspid valve surgery18 (1.3)15 (1.6)3 (0.6).100Right ventricular lead470 (28.6)295 (27.8)175 (29.9).364Atrial fibrillation1469 (90.8)941 (90.0)528 (92.3).132CAD695 (43.1)441 (42.3)254 (44.5).393NYHA functional class.004 I25 (1.5)19 (1.8)6 (1.0) II234 (14.3)167 (15.9)67 (11.5) III1181 (72.2)750 (71.3)431 (73.9) IV195 (11.9)116 (11.0)79 (13.6) Echocardiographic data TR severity.693 Moderate38 (2.3)32 (3.0)6 (1.0) Severe721 (43.9)456 (43.1)265 (45.3) Massive538 (32.7)350 (33.1)188 (32.1) Torrential347 (21.1)221 (20.9)126 (21.5) LVEF (%)53 ± 1153 ± 1152 ± 11.113 LVEDD (mm)48.3 ± 8.647.9 ± 8.548.9 ± 8.7.029 LA diameter105.3 ± 56.3103.3 ± 53.4108.9 ± 61.1.083 TR EROA (cm2)0.58 (0.41–0.79)0.59 (0.42–0.80)0.56 (0.40–0.79).143 TR Vena contracta (mm)11.2 ± 4.511.2 ± 4.811.3 ± 4.4.491 RV EDA (cm2)26.5 ± 9.626.9 ± 8.925.7 ± 10.8.039 RV ESA (cm2)16.4 ± 6.816.7 ± 6.715.9 ± 7.1.073 RV mid (mm)39.1 ± 8.939.8 ± 8.737.9 ± 9.2 <.001 RV basal (mm)49.0 ± 12.749.5 ± 9.148.3 ± 8.8.011 TV annular diameter (mm)43.3 ± 8.143.2 ± 8.243.3 ± 8.1.617 RAA (cm2)34 (28–42)34 (27–43)34 (28–43).213 TAPSE (mm)17.4 ± 4.617.5 ± 4.517.2 ± 4.6.311 RAP (mmHg)11.7 ± 6.711.6 ± 6.911.7 ± 6.1.945 sPAPecho (mmHg)43.4 ± 14.142.1 ± 13.445.9 ± 15.0 <.001 Coaptation gap (mm)6.2 ± 3.16.1 ± 2.96.4 ± 3.5.190 Tenting height (mm)7.6 ± 3.37.6 ± 3.47.7 ± 3.3.579 Tenting area (cm2)1.8 ± 1.11.8 ± 1.11.8 ± 1.1.722 TR etiology.750 Primary198 (13.4)130 (13.7)68 (12.9) Secondary1141 (77.3)729 (76.7)412 (78.3) Mixed138 (9.3)92 (9.7)46 (8.7) Medication MRA669 (44.3)419 (42.3)250 (48.4).025 Loop diuretics1398 (92.7)906 (91.6)492 (94.8).028 Thiazide diuretics338 (22.6)223 (22.8)115 (22.3).897 Betablocker1259 (83.4)817 (82.4)442 (85.5).245 RAAS-inhibitor835 (55.6)560 (56.7)275 (53.5).251 SGLT2-inhibitor389 (26.7)265 (27.7)124 (24.8).262Values are depicted as mean ± standard deviation, median (interquartile range) or number (percentage) as appropriate. Bold printed values indicated statisitcal significance (p<.005).CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EDA, end-diastolic area; EROA, effective regurgitant orifice area; ESA, end-systolic area; EuroSCORE, European System for Cardiac Operative Risk Evaluation; H/o , history of; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid rezeptor antagonist; PAD, peripheral arterial disease; RAA, right atrial area; RAAS, Renin–angiotensin–aldosterone system; RegVol, regurgitant volume; RV , right ventricular; RVbase, right ventricular basal diameter; RVmid, right ventricular midventricular diameter; sPAPecho, echocardiographically estimated systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TV, tricuspid valve; VC, vena contracta; VHD, valvular heart disease. * P-value for comparison of patients with and without concomitant VHD ≥ II°. Baseline characteristics of patients with and without concomitant ≥ moderate VHD Values are depicted as mean ± standard deviation, median (interquartile range) or number (percentage) as appropriate. Bold printed values indicated statisitcal significance (p<.005). CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EDA, end-diastolic area; EROA, effective regurgitant orifice area; ESA, end-systolic area; EuroSCORE, European System for Cardiac Operative Risk Evaluation; H/o , history of; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid rezeptor antagonist; PAD, peripheral arterial disease; RAA, right atrial area; RAAS, Renin–angiotensin–aldosterone system; RegVol, regurgitant volume; RV , right ventricular; RVbase, right ventricular basal diameter; RVmid, right ventricular midventricular diameter; sPAPecho, echocardiographically estimated systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TV, tricuspid valve; VC, vena contracta; VHD, valvular heart disease. * P-value for comparison of patients with and without concomitant VHD ≥ II°. Kaplan–Meier curves for survival and survival free from heart failure hospitalizations of the total study cohort. Kaplan–Meier curves show the 2-year survival and survival free from heart failure hospitalizations() of the total study cohort. HFH = heart failure hospitalizations Concomitant left-sided valve disease Concomitant VHD of any degree was frequent among patients in the EuroTR (Table 2) but predominantly due to mild mitral (60.2%) and aortic regurgitation (38.5%). Additionally, 24.8% of patients had moderate mitral regurgitation, whereas other moderate VHD and severe valvular pathologies were infrequent among patients undergoing T-TEER after exclusion of patients undergoing concomitant M-TEER. In total, 1061 patients (64.4%) presented with concomitant ≥ moderate VHD. Only 3.8% of patients had severe left-sided VHD, precluding separate fully adjusted survival analyses for this subgroup. Regarding baseline characteristics, patients with concomitant ≥ moderate VHD exhibited an older age (78.6 ± 8.3 years vs. 79.4 ± 6.8 years, P = .026), lower body mass index (BMI: 25.2 [22.7–28.5] kg/m2 vs. 24.6 [22.0–27.7] kg/m2, P < .001), and higher TRI score (5.5 ± 2.0 vs. 5.9 ± 1.9, P = .006) than patients without concomitant ≥ moderate VHD (Table 1). Patients with concomitant ≥ moderate VHD had more dilated right ventricles and an increased estimated systolic artery pressure (Table 1). Table 2Prevalence of valvular heart diseaseSeverityTRMRMSARASAny concomitant VHD*none—142 (8.6)1525 (92.6)922 (56.0)1440 (87.4)69 (4.2)1°—1052 (63.9)102 (6.2)634 (38.5)116 (7.0)1578 (95.8)2°38 (2.3)409 (24.8)20 (1.2)87 (5.3)76 (4.6)586 (35.6)3°721 (43.9)43 (2.6)—4 (0.2)15 (0.9)62 (3.8)4°538 (32.7)1 (0.1)———1 (0.1)5°347 (21.1)————AR, aortic regurgitation; AS, aortic stenosis; MR, mitral regurgitation; MS, mitral stenosis; TR, tricuspid regurgitation; VHD, valvular heart disease. *Equal or greater than. Prevalence of valvular heart disease AR, aortic regurgitation; AS, aortic stenosis; MR, mitral regurgitation; MS, mitral stenosis; TR, tricuspid regurgitation; VHD, valvular heart disease. *Equal or greater than. Impact of concomitant left-sided valve disease on survival, heart failure hospitalizations, and symptomatic outcomes Concomitant ≥ moderate VHD was associated with a significantly reduced 2-year survival rate (P < .001, Figure 3A) and reduced HFH-free survival (P = .005, Figure 3B). Supplementary Figure S2 illustrates the Kaplan–Meier curves for survival and survival free from heart failure hospitalizations for patients with concomitant mild, moderate, and severe left-sided VHD. Supplementary Figure S3 presents lesion-specific Kaplan–Meier curves for the main left-sided valve entities (MR, AS, AR, and MS), indicating that the composite ≥ moderate VHD signal is predominantly driven by MR, whereas interpretation for the less frequent lesions is limited by small numbers. Multivariate Cox regression analysis identified concomitant ≥ moderate VHD, age, emergency intervention, male sex, LVEF, and TAPSE as independent predictors of survival (Table 3). Kaplan–Meier curves of survival (A) and survival free from heart failure hospitalizations (B) of patients with and without concomitant ≥ moderate VHD. Kaplan–Meier curves show significantly reduced 2-year survival (A) and survival free from heart failure hospitalizations (B) of patients with ≥moderate VHD. HFH = heart failure hospitalizations; VHD = valvular heart disease Table 3Cox regression analysisUnivariateMultivariateHazard ratioCI P-valueHazard ratioCI P-valueConcomitant VHD ≥ 21,511.22–1.84 <.001 1.511.18–1.92 <.001Age (years)1.000.99–1.02.720Male sex1.641.32–2.04 <.0011.541.20–1.98 <.001COPD1.270.96–1.67.097Diabetes mellitus1.180.92–1.52.183H/o cardiac surgery1.421.13–1.80.0031.140.87–1.48.33H/o stroke1.140.82–1.58.434Emergency intervention3.381.60–7.15.0012.881.35–6.15.006Atrial fibrillation0.780.56–1.10.155Coronary artery disease1.451.17–1.80 <.0011.110.87–1.43.390LVEF0.980.97–0.98 <.0010.990.98–1.00.026TAPSE0.920.90–0.95 <.0010.940.91–0.97 <.001sPAPecho1.011.00–1.02.065RV FAC1.000.99–1.01.380Postprocedural TR1.371.22–1.53 <.0011.341.18–1.52 <.001Bold printed values indicated statisitcal significance (p<.005).H/o, history of; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; RV FAC, right ventricular fractional area change; sPAPecho, echocardiographically estimated systolic pulmonary artery pressure; VHD, valvular heart disease. Cox regression analysis Bold printed values indicated statisitcal significance (p<.005). H/o, history of; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; RV FAC, right ventricular fractional area change; sPAPecho, echocardiographically estimated systolic pulmonary artery pressure; VHD, valvular heart disease. Figure 4 illustrates the NYHA functional class at baseline and the latest available follow-up. Patients with concomitant ≥ moderate VHD had significantly worse NYHA functional class compared to patients without concomitant ≥ moderate VHD before and after T-TEER (P = .004 and P < .001, respectively). However, both groups showed significant improvement in NYHA functional class after T-TEER (P < .001). Pre- and post-procedural NYHA functional class of patients with and without concomitant VHD ≥ 2. The figure shows significant differences of NYHA functional class between patients with and without concomitant moderate valvular heart disease (VHD) before and after T-TEER Pre- and post-procedural severities of TR of both groups are outlined in Figure 5. Baseline TR did not differ significantly between groups (P = .693). Although both groups showed significant improvement in TR (P < .001), patients with concomitant ≥ moderate VHD had a higher degree of residual TR at discharge (P = .022). Pre- and post-procedural TR severity of patients with and without ≥ moderate VHD. The figure shows significant differences of TR severity between patients with and without concomitant moderate valvular heart disease (VHD) after T-TEER Discussion The EuroTR is the largest cohort of patients treated with T-TEER for TR to date, comprising more than 3000 patients. Using this comprehensive database, the current analysis reports for the first time the prevalence and impact of concomitant left-sided valvular heart disease in patients undergoing T-TEER. The main findings of the present analysis can be summarized as follows: Concomitant VHD was frequent among patients undergoing T-TEER (≥ mild: 95.8%, ≥ moderate: 35.6%, ≥ severe: 3.8%). Concomitant VHD was frequent among patients undergoing T-TEER (≥ mild: 95.8%, ≥ moderate: 35.6%, ≥ severe: 3.8%). Residual TR at discharge was more pronounced in patients with concomitant VHD. Residual TR at discharge was more pronounced in patients with concomitant VHD. Irrespective of concomitant VHD, patients experienced symptomatic improvement. Irrespective of concomitant VHD, patients experienced symptomatic improvement. Concomitant VHD was associated with significantly impaired 2-year survival and survival free from HFH after T-TEER. Concomitant VHD was associated with significantly impaired 2-year survival and survival free from HFH after T-TEER. Importantly, our analysis uniquely demonstrates that even moderate left-sided VHD independently predicts worse survival. This finding has direct clinical implications for patient selection and risk stratification, although concomitant VHD in this setting may act not only as a pathophysiologic contributor but also as a marker of an overall higher-risk phenotype. Recently, the first randomized controlled TRILUMINATE trial showed that T-TEER improves quality of life and reduces heart failure hospitalizations.5,6 However, despite encouraging results from multiple registries, no mortality benefit could be demonstrated, which might be attributable to differences in patient populations.7 Real-world cohorts, including the present analysis, report that patients treated with T-TEER are of higher surgical risk, that is, present with a greater burden of comorbidities, such as atrial fibrillation, pulmonary hypertension, and more severe right ventricular dysfunction.7 Accordingly, the mortality observed in our cohort was higher compared to the TRILUMINATE trial, reflecting a more comorbid patient population. Importantly, our analysis highlights that this difference in baseline risk also applies to concomitant valvular heart disease. While the TRILUMINATE and Tri-Fr trials excluded patients with significant left-sided valve disease and did not report on mild concomitant valvular heart disease, we could demonstrate that more than one-third of ‘real-world’ T-TEER patients exhibit concomitant moderate VHD. As expected, the most frequently observed valvular disease was mitral regurgitation, likely related to atrial dilation contributing to both atrial functional MR and TR. Additionally, a subset of patients presented with moderate aortic stenosis and regurgitation or mitral stenosis, as expected in an elderly patient population with the associated risk factors. Untreated severe left-sided valve disease was uncommon, reflecting contemporary clinical practice, in which these conditions are typically addressed before treatment of TR is considered, including concomitant M-TEER, which was excluded from this analysis.16,17 Treatment of patients with multivalvular disease is challenging. A complex interplay of cardiac haemodynamics complicates severity grading, and most trials have focused on single valvular diseases. Furthermore, despite the high prevalence of multivalvular disease among patients with severe valvular disease, guideline recommendations on multivalvular disease are scarce.18 These patients more often undergo additional diagnostic testing and are less frequently referred for intervention.18 To date, data on TR in the setting of multivalvular disease have largely been restricted to populations with severe left-sided valve disease and concomitant TR. In patients undergoing mitral TEER or transcatheter aortic valve implantation (TAVI), moderate to severe TR was common and consistently associated with worse long-term outcomes, including survival.19–22 Conversely, treatment of left-sided valve disease was frequently associated with a reduction in TR severity.20,21 Hence, TR was historically regarded mainly as a consequence of left-sided valve disease rather than a distinct clinical entity. Supporting this view, Genereux et al. proposed a new classification system for aortic stenosis grading beyond the echocardiographically obtained gradients.23 This system is based on the theory that even earlier stages of left-sided valve disease can cause upstream damage due to increased filling pressures and pulmonary hypertension, ultimately resulting in TR and right ventricular failure at advanced stages. Our findings partially endorse this concept. Patients with ≥moderate left-sided valve disease exhibited higher systolic pulmonary artery pressure. Furthermore, we demonstrated that even moderate concomitant left-sided valve disease was associated with increased mortality, HFH, more severe symptoms, and lower procedural success. Nevertheless, T-TEER resulted in a significant and sustained reduction of TR and meaningful symptomatic improvement at 2 years, even in patients with relevant concomitant VHD. This challenges the notion that TR is merely a bystander phenomenon secondary to left-sided valve disease. Instead, TR itself may contribute to systemic congestion, end-organ dysfunction due to hypoperfusion, and right ventricular failure with reduced cardiac output—all of which can, in turn, exacerbate left-sided valve dysfunction. Recent studies have shown that T-TEER alters left-sided haemodynamics and improves MR in a significant percentage of patients.24,25 In our patient cohort, left ventricular stroke volume increased significantly after T-TEER. These findings suggest a bidirectional interplay between right- and left-sided valve disease, rather than a unidirectional upstream effect. Of note, echocardiographic follow-up data of concomitant valve disease were not available at the time of manuscript preparation. Therefore, we cannot disentangle the relative contributions of residual TR, progression, or improvement in left-sided VHD and other comorbidities to the observed outcomes, and the proposed interplay between right- and left-sided valve disease should be considered hypothesis-generating. The higher residual TR in patients with concomitant VHD may be explained by different mechanistic concepts as follows: chronic left-sided valve disease maintains elevated left atrial and pulmonary pressures, which we demonstrated in our cohort. This may perpetuate right ventricular afterload elevation, impair RV–PA coupling, and consequently limit favourable geometric remodelling despite successful T-TEER. Greater left ventricular dimensions we found in patients with concomitant left-sided VHD might reflect left-sided disease unaffected by tricuspid repair. Conversely, larger RV dimensions in patients without left-sided VHD may suggest a TR phenotype favourable for procedural success. The results of this study once again emphasize the importance of a comprehensive assessment of TR patients in a multidisciplinary heart team consisting of interventional cardiologists, surgeons, heart failure specialists, and electrophysiologists. Concomitant cardiac and extracardiac pathologies must be addressed as completely as possible to maximize the benefit of tricuspid valve interventions. In patients undergoing cardiac surgery, valve repair or replacement should be as complete as reasonably achievable to minimize the risk of repeat surgery. For transcatheter therapies, retrospective data have shown that after M-TEER, the rate of concomitant TR ≥2 + reduces around 10% (56% to 45%).26 However, predicting a respective improvement remains challenging. In a propensity-matched analysis from the TRAMI and TRIVALVE registry, concomitant M- and T-TEER was associated with better survival compared with isolated M-TEER in patients with both MR and TR.8 Nevertheless, randomized controlled studies are required in order to be able to provide a clear recommendation regarding simultaneous treatment of MR and TR. Further studies are needed to not only report the impact of concomitant baseline VHD on outcomes after T-TEER but also investigate the potential changes in concomitant valvular pathologies after TR treatment. Study limitations Despite using data from the largest multicentre registry of patients undergoing T-TEER, this study has inherent limitations. Data collection was based on site-reported information without confirmation by an independent echocardiographic core laboratory, which represents a critical limitation. VHD grading—particularly moderate lesions—is operator-dependent and prone to interobserver variability, with no systematic variability data available in EuroTR. Misclassification may have biased estimates in either direction; hence, the results require cautious interpretation and validation in core lab-adjudicated cohorts. A subset of patients lacked complete echocardiographic data and were therefore excluded. At the time of manuscript preparation, follow-up echocardiographic data on concomitant valve disease were not available, representing a major limitation of the study, as it prevented assessment of temporal changes of concomitant VHD and therefore restricts mechanistic interpretation. Patients with concomitant moderate VHD showed slightly higher utilization of diuretics at baseline, but these differences likely reflect disease severity rather than differential therapeutic strategies confounding the prognostic signal. Furthermore, patients with ≥moderate left-sided VHD had higher TRI-score, more advanced RV remodelling, and higher pulmonary pressures at baseline, indicating more severe global cardiopulmonary disease. Although we adjusted our multivariable models for several clinical and echocardiographic covariates, residual confounding cannot be excluded, and concomitant left-sided VHD in this cohort may represent a marker of advanced cardiopulmonary disease rather than an isolated causal determinant of outcome. While lesion-specific Kaplan–Meier curves are shown in Supplementary Figure S3, the low prevalence of non-MR lesions precluded fully adjusted models for each valve entity, limiting generalizability beyond MR. Conclusion In the largest T-TEER registry to date, patients presented with a high prevalence of multivalvular disease. Concomitant left-sided valve disease was associated with increased mortality and heart failure hospitalizations. T-TEER was associated with significant TR reduction and symptomatic improvement regardless of concomitant valve disease, but given the observational design and absence of follow-up imaging, these findings must be interpreted cautiously. Prospective studies are needed to validate these observations and to clarify the mechanistic interplay between right- and left-sided valve disease. Supplementary Material Contributor Information Jonas Gmeiner, Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany. Lukas Stolz, Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. Karl-Patrik Kresoja, Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. Jennifer von Stein, Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. Vera Fortmeier, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany. Christoph Pauschinger, Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany. Wolfgang Rottbauer, Ulm University Heart Center, Ulm, Germany. Mohammad Kassar, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Switzerland. Bjoern Goebel, Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany. Paolo Denti, Heart Valve Center, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. Paul Achouh, Cardiology Department, European Hospital Georges Pompidou, Université Paris Cité, Paris, France. Tienush Rassaf, Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Manuel Barreiro-Perez, Hospital Álvaro Cunqueiro, Vigo, Spain. Peter Boekstegers, Department of Cardiology, Helios Klinikum Siegburg, Siegburg, Germany. Andreas Rück, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. Monika Zdanyte, Medical Clinic III, University Hospital Tübingen, Tübingen, Germany. Marianna Adamo, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. Flavien Vincent, Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France. Philipp Schlegel, Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg 69120, Germany. Sebastian Rosch, Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. Mirjam G Wild, Department of Cardiology and Angiology, Medical Center, Faculty of Medicine, University Heart Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. Christian Besler, Department of Cardiology and Angiology, Medical Center, Faculty of Medicine, University Heart Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. Stefan Toggweiler, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland. Stephanie Brunner, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland. Julia Grapsa, Department of Cardiology, Guys and St Thomas NHS Trust, London, UK. Tiffany Patterson, Department of Cardiology, Guys and St Thomas NHS Trust, London, UK. Holger Thiele, Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. Tobias Kister, Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. Giuseppe Tarantini, Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy. Giulia Masiero, Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy. Marco De Carlo, University of Pisa, Pisa, Italy. Alessandro Sticchi, University of Pisa, Pisa, Italy. Fabian Voss, Department of Cardiology, Pulmonology and Angiology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf 40225, Germany. Amin Polzin, Department of Cardiology, Pulmonology and Angiology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf 40225, Germany. Antonio Popolo Rubbio, Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. Francesco Bedogni, Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. Thorald Stolte, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. Thomas Nestelberger, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. Thomas Benito-Gonzales, Departamento de Cardiología, Complejo Asistencial Universitario de León, León, Spain. Enrique Sánchez-Muñóz, Departamento de Cardiología, Complejo Asistencial Universitario de León, León, Spain. Mathias H Konstandin, Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg 69120, Germany. Eric Van Belle, Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France. Marco Metra, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. Tobias Geisler, Medical Clinic III, University Hospital Tübingen, Tübingen, Germany. Rodrigo Estévez-Loureiro, Hospital Álvaro Cunqueiro, Vigo, Spain. Amir Abbas Mahabadi, Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Nicole Karam, Cardiology Department, European Hospital Georges Pompidou, Université Paris Cité, Paris, France. Francesco Maisano, Heart Valve Center, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. Philipp Lauten, Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany. Fabien Praz, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Mirjam Kessler, Ulm University Heart Center, Ulm, Germany. Daniel Kalbacher, Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany. Volker Rudolph, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany. Christos Iliadis, Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. Philipp Lurz, Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. Jörg Hausleiter, Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. the EuroTR Investigators: Julia Novotny, Ludwig T Weckbach, Thomas J Stocker, Kaspar Volz, Katalin Berschiminski, Philipp Doldi, Hannah Kempton, Dario Grassini, Clemens Scherer, Karl-Philip Rommel, Ralph Stephan von Bardeleben, Roman Pfister, Stephan Baldus, Philipp von Stein, Muhammed Gerçek, Felix Rudolph, Sebastian Ludwig, Benedikt Koell, Leonhard-Moritz Schneider, Dominik Felbel, Carsten Salomon, Harald Lapp, Quentin de Baynast, Alain Berrebi, Florian Schindhelm, Berenice Caneiro-Queija, Julio Echarte-Morales, Andreas Goldschmied, Edoardo Pancaldi, Elisa Pezzola, Mauro Massussi, Laura Lupi, Natacha Rousse, Samy Aghezzaf, Norbert Frey, Martin Kraus, Dirk Westermann, Federico Arturi, and Anke von Peter Supplementary data Supplementary data are available at ESC Heart Failure online. Declarations Disclosure of Interest Lukas Stolz received speaker honoraria from Edwards Lifesciences. Karl-Patrik Kresoja reports travel expenses from Edwards Lifesciences. Jennifer von Stein received Lecture honoraria from Edwards Lifesciences. Wolfgang Rottbauer received speaker honoraria Edwards and Abbott. Paolo Denti served as Consultant for InnovHeart, Picardia, HVR, Approxima and received Speaker Honoraria from Abbott and Edwards. Tienush Rassaf received speaker honoraria and consulting fees from Astra Zeneca, Bayer, Pfizer, Daiichi Sankyo. Manuel Barreiro-Perez received speaker fees from Abbott Vascular, Edwards Lifesciences and Venus Medtech. Marianna Adamo received consulting fees in the last three years from Abbott Structural Heart and Edwards LifeSciences. Stefan Toggweiler has received personal honoraria from Medtronic, Boston Scientific, Biosensors, Abbott Vascular, Medira, Shockwave, Teleflex, atHeart Medical, Cardiac Dimensions, Polares Medical, Amarin, Sanofi, AstraZeneca, ReCor Medical, Daiichi Sankyo, has received institutional research grants from Edwards Lifesciences, Boston Scientific, Fumedica, Novartis, Boehringer Ingelheim, and holds equity in Hi-D Imaging. Marco Metra received consulting fees in the last three years from Abbott Structural Heart, Astra-Zeneca, Bayer, Boheringer Ingelheim, Edwards LifeSciences, Roche Diagnostics. Tobias Geisler received speaker honoraria/research grants from Astra Zeneca, Bayer, Bristol Myers Squibb/Pfizer, Ferrer/Chiesi, Medtronic and Edwards Lifesciences. None of them was related to this study. Rodrigo Estévez-Loureiro received speaker fees from Abbott Vascular, Edwards Lifesciences, Boston Scientific and Venus Medtech. Francesco Maisano received Grant and/or Research Institutional Support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo, Venus and Consulting fees, Honoraria personal and Institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Mtex, Venus, Squadra, Valgen Royalty Income/IP Rights Edwards Lifesciences and is shareholder (including share options) of Magenta, Transseptalsolutions, 4Tech. Fabien Praz received Travel expenses from Edwards Lifesciences, Abbott Vascular, Polares Medical, Medira, and Siemens Healthineers. Mirjam Kessler received speaker honoraria Edwards and Abbott. Daniel Kalbacher has received personal fees from Abbott Medical, Edwards Lifesciences, Pi-Cardia Ltd and Medtronic Inc. Volker Rudolph received Research grants from Abbott Medical, Boston Scientific, and Edwards Lifesciences. Christos Iliadis received consultant fees and travel expenses from Abbott Medical and Edwards LifeSciences. Alessandro Sticchi served on the advisory board for Edwards Lifesciences. Philipp Lurz received institutional grants from Edwards Lifesciences and honoraria from Innoventrics. Jörg Hausleiter reports research grant support and speaker honoraria from Edwards Lifesciences. All other authors have no relevant conflicts of interest to declare. Giuseppe Tarantini received speaker fee for Abbott Vascular and Edwards Lifesciences. Amir Mahabadi received peaker fees and/or advisory boards: Amgen, Berlin Chemie, Daiichi Sankyo, Edwards, Novartis, Sanofi. Research funding: Daiichi Sankyo, Edwards, all outside the submitted work. Mark Lachmann has received funding from the Technical University of Munich (Clinician Scientist Grant), from the Else Kröner-Fresenius Foundation (Clinician Scientist Grant), from the German Center for Cardiovascular Research (DZHK; Postdoc Start-up Grant on Advancing Digital Aspects), and from the German Heart Foundation (‘Machine learning in severe mitral regurgitation’). Thomas Nestelberger has received research support from the Swiss National Science Foundation (P400PM_191037/1), the Prof. Dr. Max Cloëtta Foundation, the Margarete und Walter Lichtenstein-Stiftung (3MS1038), the Freiwillige Akademische Gesellschaft Basel, the Stiftung kardiovaskuläre Forschung Basel, the University of Basel, the University Hospital Basel as well as speaker/consulting honoraria or research support from Edwards Lifesciences, Pronova Medical, Meril, Boston Scientific, Medtronic, Abbott, Beckman Coulter, Bayer, Ortho Clinical Diagnostics and Orion Pharma, outside the submitted work. Data Availability No data were generated or analysed for this manuscript. Funding Among the full cohort of patients in the registry, data collection for the Hamburg patients was supported by a grant from the German Heart Foundation. Ethical Approval Ethical Approval was not required. Pre-registered Clinical Trial Number None supplied. Appendix ‡PubMed indexed investigator list: Julia Novotny (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany), Ludwig T. Weckbach (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany; Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Switzerland), Thomas J. Stocker (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich; Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Switzerland), Kaspar Volz (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich), Katalin Berschiminski (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich), Philipp Doldi (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich), Hannah Kempton (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich; Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany), Dario Grassini (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany), Clemens Scherer (Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich), Karl-Philip Rommel (Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany), Ralph Stephan von Bardeleben (Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany), Roman Pfister (Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany), Stephan Baldus (Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany), Philipp von Stein (Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany), Muhammed Gerçek (Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany), Felix Rudolph (Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany), Sebastian Ludwig (Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany), Benedikt Koell (Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany), Leonhard-Moritz Schneider (Ulm University Heart Center, Ulm, Germany), Dominik Felbel (Ulm University Heart Center, Ulm, Germany), Carsten Salomon (Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany), Harald Lapp (Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany), Quentin de Baynast (Cardiology Department, European Hospital Georges Pompidou, Université Paris Cité, Paris, France), Alain Berrebi (Cardiology Department, European Hospital Georges Pompidou, Université Paris Cité, Paris, France), Florian Schindhelm (Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany), Berenice Caneiro-Queija (Hospital Álvaro Cunqueiro, Vigo, Spain), Julio Echarte-Morales (Hospital Álvaro Cunqueiro, Vigo, Spain), Andreas Goldschmied (Medical Clinic III, University Hospital Tübingen, Tübingen, Germany), Edoardo Pancaldi (ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy), Elisa Pezzola (ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy), Mauro Massussi (ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy), Laura Lupi (ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy), Natacha Rousse (Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France), Samy Aghezzaf (Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France), Norbert Frey (Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg 69120, Germany), Martin Kraus (Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg 69120, Germany), Dirk Westermann (University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany), Federico Arturi (Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy), Anke von Peter (Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Switzerland). References Associated Data Supplementary Materials Data Availability Statement No data were generated or analysed for this manuscript.